The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory [PDF]
iScience, 2021 ABSTRACTVaccines based on mRNA-containing lipid nanoparticles (LNPs) are a promising new platform used by two leading vaccines against coronavirus disease in 2019 (COVID-19). Clinical trials and ongoing vaccinations present with very high protection levels and varying degrees of side effects.
Ndeupen, Sonia +5 more
openaire +5 more sources
Exploring the HYDRAtion method for loading siRNA on liposomes : the interplay between stability and biological activity in human undiluted ascites fluid [PDF]
, 2016 Delivery of small interfering RNA (siRNA) is recently gaining tremendous attention for the treatment of ovarian cancer. The present study investigated the potential of different liposomal formulations composed of (2,3-dioleoyloxy-propyl)trimethylammonium
Braeckmans, Kevin +4 more
core +2 more sources
Expression kinetics and innate immune response after electroporation and LNP-mediated delivery of a self-amplifying mRNA in the skin [PDF]
, 2019 In this work, we studied the expression kinetics and innate immune response of a self-amplifying mRNA (sa-RNA) after electroporation and lipid-nanoparticle (LNP)-mediated delivery in the skin of mice. Intradermal electroporation of the sa-RNA resulted in
De Temmerman, Joyca +8 more
core +2 more sources
A Combinatorial Library of Lipid Nanoparticles for Cell Type‐Specific mRNA Delivery
Advanced Science, 2023 Ionizable lipid‐based nanoparticles (LNPs) are the most advanced non‐viral drug delivery systems for RNA therapeutics and vaccines. However, cell type‐specific, extrahepatic mRNA delivery is still a major hurdle, hampering the development of novel ...
Gonna Somu Naidu +10 more
doaj +1 more source
Investigation of enzyme-sensitive lipid nanoparticles for delivery of siRNA to blood–brain barrier and glioma cells [PDF]
, 2015 Clinical applications of siRNA for treating disorders in the central nervous system require development of systemic stable, safe, and effective delivery vehicles that are able to cross the impermeable blood–brain barrier (BBB).
Andresen, Thomas Lars +6 more
core +1 more source
Antimicrobial Nanoplexes meet Model Bacterial Membranes: the key role of Cardiolipin [PDF]
, 2017 Antimicrobial resistance to traditional antibiotics is a crucial challenge of medical research. Oligonucleotide therapeutics, such as antisense or Transcription Factor Decoys (TFDs), have the potential to circumvent current resistance mechanisms by ...
A Meister +44 more
core +8 more sources
Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling [PDF]
, 2013 Despite substantial efforts to understand the interactions between nanoparticles and cells, the cellular processes that determine the efficiency of intracellular drug delivery remain largely unclear. Here we examined cellular uptake of siRNA delivered in
A Akinc +54 more
core +2 more sources
In Vitro-In Vivo Translation of Lipid Nanoparticles for Hepatocellular siRNA Delivery [PDF]
, 2012 A significant challenge in the development of clinically viable siRNA delivery systems is a lack of in vitro–in vivo translatability: many delivery vehicles that are initially promising in cell culture do not retain efficacy in animals.
Anderson, Daniel Griffith +6 more
core +1 more source
Frontiers in Pharmacology, 2019 Drugs are administered orally in the clinical treatment of hypertension. Antihypertensive peptides have excellent angiotensin converting enzyme inhibitors activity in vitro.
Shengnan Zhao +10 more
doaj +1 more source
Identification of Novel Fibrosis Modifiers by In Vivo siRNA Silencing. [PDF]
, 2017 Fibrotic diseases contribute to 45% of deaths in the industrialized world, and therefore a better understanding of the pathophysiological mechanisms underlying tissue fibrosis is sorely needed.
Amatucci, Aldo +16 more
core +2 more sources